Abstract
Ado-trastuzumab emtansine (Kadcyla—Genentech) has received FDA approval for the management of human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer. The therapy is specifi cally indicated for those who have already undergone unsuccessful treatment with trastuzumab (Herceptin—Genentech) and a taxane. Trastuzumab emtansine is an antibody–drug conjugate comprising the antibody trastuzumab and the chemotherapy drug DM1 attached using a stable linker.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
